🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 377322102
- Market Cap
- Large Cap
- IPO
- 6/24/2015 · $18.00/share
Business: Glaukos Corp. is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The Company has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm.
Notes: Oct 17 2019 -- Avedro, Glaukos Corporation, a Delaware corporation ("Glaukos"), and Atlantic Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Glaukos ("Merger Sub"), have entered into an Agreement and Plan of Merger, dated as of August 7, 2019 (the "Merger Agreement"), pursuant to which, among other things, Merger Sub will merge with and into Avedro, with Avedro continuing as the surviving corporation (the "Merger"). The board of directors of Avedro unanimously approved and the board of directors of Glaukos (with Mr. Thomas W. Burns recusing himself) approved the Merger and related transactions. If the Merger is completed, at the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001, of Avedro ("Avedro Common Stock") that is issued and outstanding immediately prior to the Effective Time will be automatically cancelled and converted into the right to receive a number of shares of common stock, par value $0.001, of Glaukos ("Glaukos Common Stock") equal to the product of the number of shares of Avedro Common Stock multiplied by 0.365 (the "Exchange Ratio"). The Exchange Ratio is fixed and will not be adjusted to reflect changes in the price of Avedro Common Stock or Glaukos Common Stock prior to the closing of the Merger.
Company Contact
- CEO
- Thomas W. Burns
- CFO
- Alex R. Thurman
- Headquarters
- 229 Avenida Fabricante, San Clemente, CA 92672
- Phone
- 949-367-9600
- Fax
- 949-367-9984
- Investor Relations
- Chris Lewis · 949-481-0510 · clewis@glaukos.com